Insider Selling: eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) Major Shareholder Sells $21,095.37 in Stock

eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR – Get Rating) major shareholder Presidio Management Group X. Ll sold 26,703 shares of the firm’s stock in a transaction on Monday, August 1st. The shares were sold at an average price of $0.79, for a total transaction of $21,095.37. Following the transaction, the insider now directly owns 130,218 shares of the company’s stock, valued at approximately $102,872.22. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

eFFECTOR Therapeutics Trading Up 0.7 %

Shares of NASDAQ EFTR opened at $0.82 on Friday. eFFECTOR Therapeutics, Inc. has a twelve month low of $0.75 and a twelve month high of $40.42. The firm has a fifty day simple moving average of $1.32 and a 200 day simple moving average of $3.08. The company has a debt-to-equity ratio of 0.75, a current ratio of 18.38 and a quick ratio of 18.38.

eFFECTOR Therapeutics (NASDAQ:EFTR – Get Rating) last announced its earnings results on Tuesday, May 10th. The company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.39. On average, equities research analysts predict that eFFECTOR Therapeutics, Inc. will post -0.52 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, JMP Securities reaffirmed a “buy” rating and set a $8.00 price target on shares of eFFECTOR Therapeutics in a research note on Monday, June 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, eFFECTOR Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $19.64.

Hedge Funds Weigh In On eFFECTOR Therapeutics

Hedge funds have recently bought and sold shares of the company. State Street Corp bought a new position in eFFECTOR Therapeutics during the first quarter worth $68,000. Resolute Financial LLC acquired a new stake in eFFECTOR Therapeutics in the second quarter worth $43,000. Alps Advisors Inc. acquired a new stake in eFFECTOR Therapeutics in the fourth quarter worth $430,000. Parallel Advisors LLC acquired a new stake in eFFECTOR Therapeutics in the first quarter worth $2,744,000. Finally, OUP Management Co. LLC acquired a new stake in eFFECTOR Therapeutics in the fourth quarter worth $8,493,000. Institutional investors own 51.71% of the company’s stock.

About eFFECTOR Therapeutics

(Get Rating)

eFFECTOR Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer.